Stocks / NASDAQ / Gyre Therapeutics Inc.

Gyre Therapeutics Inc.

Our Opinion

Gyre Therapeutics Inc. is on the Cruelty Free Investing list for exploiting animals because the company does animal testing for some of their medical analysis and clinical research.

Supporting Evidence:

The company stated in the following report that they exploit animals for product testing.

“Gyre believes that Hydronidone may offer a potent anti-fibrotic therapeutic option for MASH fibrosis. The key attributes of the molecular mechanism of action of Hydronidone that support the proposed clinical investigation in MASH fibrosis include inhibition of Hepatic Stellate Cells (HSCs) activation via Smad7-mediated TGFβRI degradation that led in animal liver fibrosis model to attenuation of liver fibrosis, decreased collagen accumulation, and reduced the expression of fibrosis-related genes in HSCs (Xu X et al. Liver International 2023).” Read the following article

Company Description

Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. It offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under phase 3 studies for dermatomyositis and systemic sclerosis-associated interstitial lung disease, pneumoconiosis, and diabetic kidney disease. The company was founded in 2002 and is headquartered in San Diego, California. Gyre Therapeutics, Inc. operates as a subsidiary of GNI USA, Inc.

Company Website: